Opportunity Information: Apply for PA 25 123

The National Institutes of Health (NIH) is offering a discretionary grant opportunity titled "Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R21 Clinical Trial Not Allowed)" under Funding Opportunity Number PA 25 123 (CFDA 93.393). The goal of this announcement is to support early-stage, innovative epidemiologic studies that test new hypotheses about what is driving liver cancer risk in the United States, with a clear emphasis on emerging risk factors and how they may interact with well-established causes such as viral hepatitis. The FOA focuses on liver cancer broadly, including hepatocellular carcinoma as well as other histologic subtypes, and it is designed to stimulate creative, hypothesis-driven research that can open up new directions for prevention and risk stratification.

At its core, this opportunity is aimed at epidemiology, meaning studies that use population-based data, cohorts, registries, biospecimens linked to health data, or other human data resources to understand patterns, causes, and susceptibility. NIH is specifically encouraging research on emerging biological, environmental, and social risk factors. That can include newer or rapidly changing exposures (for example, shifts in metabolic health and obesity-related pathways, evolving environmental contaminants, changing patterns of medication or substance use, or social and structural determinants that influence exposure, diagnosis, and outcomes). A central theme is interplay: applicants are encouraged to look at how these newer factors combine with established risks like chronic hepatitis B or C infection, potentially altering risk levels, changing disease trajectories, or creating distinct high-risk subgroups that could be targeted for screening or prevention.

The mechanism is an R21, which is NIH's exploratory/developmental grant format. In practical terms, that signals support for projects that are novel, potentially high-impact, and may be earlier in development than a larger, longer R01-style project. These projects often prioritize proof-of-concept analyses, development of new epidemiologic approaches, or testing of innovative hypotheses that can justify larger follow-on studies. The listing also clearly states "Clinical Trial Not Allowed," which means proposals should not include prospective interventional studies where participants are assigned to receive a treatment or behavioral intervention to evaluate health outcomes. Observational epidemiologic research is the intended fit, including analyses of existing data or biospecimens, population-based observational designs, and other non-interventional human research approaches.

Eligibility is broad and includes many types of U.S. organizations and governmental units. Eligible applicants include state, county, city, township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations that are not federally recognized governments; public housing authorities and Indian housing authorities; nonprofits with or without 501(c)(3) status (as long as they are not institutions of higher education); for-profit organizations other than small businesses; and small businesses. In addition, NIH explicitly notes several other eligible applicant categories, such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, U.S. territories or possessions, regional organizations, and even non-U.S. entities (foreign organizations). This broad eligibility creates room for academic, public health, community, and cross-sector groups to propose studies that reflect diverse populations and real-world exposure contexts.

Key administrative details provided include an original closing date of 2025-05-07 and a creation date of 2024-10-10. The source information does not list an award ceiling or the expected number of awards, so applicants would typically confirm budget limits and award expectations by consulting the full FOA text and related NIH policy pages. Overall, the opportunity is best suited for teams with access to relevant population data or specimens and a strong epidemiologic plan to examine emerging liver cancer risk drivers in the U.S., especially studies that can clarify who is most susceptible and why, and that can lay groundwork for improved prevention, early detection strategies, or future larger-scale investigations.

  • The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R21 Clinical Trial Not Allowed)" and is now available to receive applicants.
  • Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.393.
  • This funding opportunity was created on 2024-10-10.
  • Applicants must submit their applications by 2025-05-07. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
  • Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
Apply for PA 25 123

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:

Browse more opportunities from the same agency: National Institutes of Health

Browse more opportunities from the same category: Education, Health

Next opportunity: Computational Approaches to Curation at Scale for Biomedical Research Assets (R01 Clinical Trial Not Allowed)

Previous opportunity: OJJDP FY24 Invited to Apply – Administrative Funding Adjustment to Previously Funded Award OJJDP FY21 Title II Formula Grants Program

Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for PA 25 123

 

Applicants also applied for:

Applicants who have applied for this opportunity (PA 25 123) also looked into and applied for these:

Funding Opportunity
Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R01 Clinical Trial Not Allowed) Apply for PA 25 121

Funding Number: PA 25 121
Agency: National Institutes of Health
Category: Education, Health
Funding Amount: Case Dependent
Limited Competition: NCI National Clinical Trials Network - Network Group Operations Centers (U10 Clinical Trial Required) Apply for RFA CA 24 030

Funding Number: RFA CA 24 030
Agency: National Institutes of Health
Category: Education, Health
Funding Amount: Case Dependent
Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01 Clinical Trial Not Allowed) Apply for PAR 24 304

Funding Number: PAR 24 304
Agency: National Institutes of Health
Category: Education, Health
Funding Amount: Case Dependent
NCI National Clinical Trials Network - Network Lead Academic Participating Sites (UG1 Clinical Trial Not Allowed) Apply for RFA CA 24 033

Funding Number: RFA CA 24 033
Agency: National Institutes of Health
Category: Education, Health
Funding Amount: $1,700,000
Single Source: NCI National Clinical Trials Network - Canadian Collaborating Clinical Trials Network (U10 Clinical Trial Required) Apply for RFA CA 24 032

Funding Number: RFA CA 24 032
Agency: National Institutes of Health
Category: Education, Health
Funding Amount: Case Dependent
Interventions to expand cancer screening and preventive services to ADVANCE health in populations that experience health disparities (R01, Clinical Trial Required) Apply for PAR 25 098

Funding Number: PAR 25 098
Agency: National Institutes of Health
Category: Education, Health
Funding Amount: Case Dependent
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed) Apply for PAR 25 075

Funding Number: PAR 25 075
Agency: National Institutes of Health
Category: Education, Health
Funding Amount: $250,000
Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R34 Clinical Trial Optional) Apply for RFA DA 25 070

Funding Number: RFA DA 25 070
Agency: National Institutes of Health
Category: Education, Health
Funding Amount: $450,000
Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R01 Clinical Trial required) Apply for RFA DA 25 072

Funding Number: RFA DA 25 072
Agency: National Institutes of Health
Category: Education, Health
Funding Amount: Case Dependent
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed) Apply for PAR 25 074

Funding Number: PAR 25 074
Agency: National Institutes of Health
Category: Education, Health
Funding Amount: Case Dependent
Screening, Brief Intervention and Referral to Treatment or Prevention (SBIRT/P) for alcohol, tobacco, and other drugs (ATOD) use and misuse in adult populations that experience health disparities (R01, Clinical Trial Required) Apply for PAR 26 001

Funding Number: PAR 26 001
Agency: National Institutes of Health
Category: Education, Health
Funding Amount: Case Dependent
Co-infection and Cancer (R01 Clinical Trial Not Allowed) Apply for PAR 25 082

Funding Number: PAR 25 082
Agency: National Institutes of Health
Category: Education, Health
Funding Amount: Case Dependent
NCI Small Grants Program for Cancer Research (NCI Omnibus) (R03 Clinical Trial Optional) Apply for PAR 25 078

Funding Number: PAR 25 078
Agency: National Institutes of Health
Category: Education, Health
Funding Amount: $50,000
The Metastasis Research Network (MetNet): MetNet Research Projects (U01 Clinical Trial Not Allowed) Apply for PAR 25 130

Funding Number: PAR 25 130
Agency: National Institutes of Health
Category: Education, Health
Funding Amount: $500,000
Targeting Inflammasomes in HIV and Substance Use (R21 Clinical Trial Not Allowed) Apply for RFA DA 25 068

Funding Number: RFA DA 25 068
Agency: National Institutes of Health
Category: Education, Health
Funding Amount: $500,000
Computational Approaches to Curation at Scale for Biomedical Research Assets (R01 Clinical Trial Not Allowed) Apply for PAR 25 131

Funding Number: PAR 25 131
Agency: National Institutes of Health
Category: Education, Health
Funding Amount: $250,000
Targeting Inflammasomes in HIV and Substance Use (R01 Clinical Trial Not Allowed) Apply for RFA DA 25 069

Funding Number: RFA DA 25 069
Agency: National Institutes of Health
Category: Education, Health
Funding Amount: $500,000
Biomedical Research Environment and Sponsored Programs Administration Development (BRE-SPAD) Program (UC2- Clinical Trial Not Allowed) Apply for PAR 24 268

Funding Number: PAR 24 268
Agency: National Institutes of Health
Category: Education, Health
Funding Amount: $500,000
Mechanistic links between diet, lipid metabolism, and tumor growth and progression (UH2 Clinical Trial Not Allowed) Apply for PAR 25 118

Funding Number: PAR 25 118
Agency: National Institutes of Health
Category: Education, Health
Funding Amount: Case Dependent
Enhancing Mechanistic Research on Precision Probiotic Therapies (R61/R33 Clinical Trial Optional) Apply for PAR 25 211

Funding Number: PAR 25 211
Agency: National Institutes of Health
Category: Education, Health
Funding Amount: Case Dependent

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

Inside Our Applicants Portal

  • Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
  • Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
  • Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Access Applicants Portal

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Learn More

 

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "PA 25 123", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.

 

Ask a Question: